Get the Stockscreener App
1.544
1.66%
-0.026
Aprea Therapeutics Inc stock is traded at $1.544, with a volume of 42,124.
It is down -1.66% in the last 24 hours and down -9.18% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.57
Open:
$1.58
24h Volume:
42,124
Relative Volume:
0.86
Market Cap:
$8.99M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.387
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-0.39%
1M Performance:
-9.18%
6M Performance:
-36.20%
1Y Performance:
-54.85%
1-Day Range:
$1.544
$1.605
1-Week Range:
$1.53
$1.665
52-Week Range:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.544 | 9.00M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
What does recent volatility data suggest for Aprea Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - Newser
Will Aprea Therapeutics Inc. stock go up soonJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Can trapped investors hope for a rebound in Aprea Therapeutics Inc.Options Play & Community Driven Trade Alerts - Newser
Applying chart zones and confluence areas to Aprea Therapeutics Inc.Portfolio Profit Report & Real-Time Buy Zone Alerts - Newser
What earnings revisions data tells us about Aprea Therapeutics Inc.July 2025 Pullbacks & Weekly High Potential Stock Alerts - Newser
Chart based exit strategy for Aprea Therapeutics Inc.Trade Entry Report & Safe Capital Growth Plans - Newser
What institutional flow reveals about Aprea Therapeutics Inc.Exit Point & AI Driven Price Predictions - Newser
Price action breakdown for Aprea Therapeutics Inc.Market Activity Report & Weekly Chart Analysis and Guides - Newser
Chart based analysis of Aprea Therapeutics Inc. trendsWeekly Volume Report & Free Reliable Trade Execution Plans - Newser
Relative strength of Aprea Therapeutics Inc. in sector analysis2025 Technical Patterns & Fast Entry High Yield Tips - Newser
Visual analytics tools that track Aprea Therapeutics Inc. performanceJuly 2025 Technicals & Safe Capital Growth Plans - Newser
Visual trend scoring systems applied to Aprea Therapeutics Inc.July 2025 Price Swings & Free Expert Approved Momentum Trade Ideas - Newser
Using R and stats models for Aprea Therapeutics Inc. forecastingProfit Target & Daily Oversold Stock Bounce Ideas - Newser
Aprea Therapeutics Inc.’s volatility index tracking explained2025 Price Action Summary & Safe Entry Trade Reports - Newser
Is Aprea Therapeutics Inc. stock entering bullish territory2025 Price Targets & Smart Allocation Stock Reports - Newser
How to use a screener to detect Aprea Therapeutics Inc. breakoutsQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
What technical models suggest about Aprea Therapeutics Inc.’s comebackJuly 2025 Price Swings & Accurate Intraday Trading Signals - Newser
Is now a turning point for Aprea Therapeutics Inc.Weekly Trend Summary & High Accuracy Trade Signal Alerts - Newser
How moving averages guide Aprea Therapeutics Inc. tradingJuly 2025 Chart Watch & Free High Return Stock Watch Alerts - Newser
Full technical analysis of Aprea Therapeutics Inc. stockQuarterly Profit Report & Reliable Intraday Trade Alerts - Newser
Will a bounce in Aprea Therapeutics Inc. offer an exitIPO Watch & Fast Moving Market Watchlists - Newser
Chart overlay techniques for tracking Aprea Therapeutics Inc.Forecast Cut & Stock Portfolio Risk Control - Newser
Using Ichimoku Cloud for Aprea Therapeutics Inc. technicalsJuly 2025 Review & Risk Controlled Swing Trade Alerts - Newser
Is Aprea Therapeutics Inc. stock technically oversoldWeekly Risk Report & Risk Adjusted Swing Trade Ideas - Lancaster City Council
What hedge funds are buying Aprea Therapeutics Inc.Weekly Trade Review & Community Verified Trade Alerts - Lancaster City Council
Is Aprea Therapeutics Inc. gaining market shareTrade Volume Report & High Accuracy Swing Entry Alerts - Lancaster City Council
Aprea Therapeutics Inc. recovery potential after sell offJuly 2025 PostEarnings & Fast Entry Momentum Trade Alerts - Newser
Using RSI to spot recovery in Aprea Therapeutics Inc.Market Sentiment Report & Real-Time Volume Analysis - Newser
Can technical indicators confirm Aprea Therapeutics Inc.’s reversalGap Up & Low Risk High Win Rate Stock Picks - Newser
Can a trend reversal in Aprea Therapeutics Inc. lead to recoveryWeekly Trade Summary & Daily Volume Surge Signals - Newser
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):